SciClone Pharmaceuticals Inc. (SCLN) Research Coverage Started at Maxim Group
Maxim Group started coverage on shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) in a research report sent to investors on Monday. The firm issued a buy rating and a $14.00 price target on the specialty pharmaceutical company’s stock.
“SciClone is a US-based specialty pharma company with its operating focus on the China pharmaceuticals market.”,” the firm’s analyst commented.
SciClone Pharmaceuticals (NASDAQ:SCLN) opened at 9.95 on Monday. SciClone Pharmaceuticals has a 12 month low of $7.36 and a 12 month high of $15.02. The stock has a market cap of $507.98 million, a PE ratio of 14.21 and a beta of 1.65. The company has a 50-day moving average of $9.76 and a 200-day moving average of $11.20.
COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the propert of of Daily Political. If you are viewing this report on another publication, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this report can be read at http://www.dailypolitical.com/2016/12/01/sciclone-pharmaceuticals-inc-scln-research-coverage-started-at-maxim-group.html.
In other news, CFO Wilson Wai-Shun Cheung sold 149,962 shares of the stock in a transaction on Wednesday, October 26th. The shares were sold at an average price of $10.00, for a total value of $1,499,620.00. Following the completion of the sale, the chief financial officer now directly owns 15,064 shares of the company’s stock, valued at $150,640. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Friedhelm Blobel sold 30,000 shares of the stock in a transaction on Monday, November 14th. The stock was sold at an average price of $10.27, for a total transaction of $308,100.00. The disclosure for this sale can be found here. Company insiders own 7.63% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. GWM Advisors LLC purchased a new stake in shares of SciClone Pharmaceuticals during the third quarter worth about $104,000. Mason Street Advisors LLC purchased a new stake in shares of SciClone Pharmaceuticals during the second quarter worth about $127,000. Acrospire Investment Management LLC boosted its stake in shares of SciClone Pharmaceuticals by 190.0% in the third quarter. Acrospire Investment Management LLC now owns 12,782 shares of the specialty pharmaceutical company’s stock worth $131,000 after buying an additional 8,375 shares during the period. Aperio Group LLC boosted its stake in shares of SciClone Pharmaceuticals by 14.7% in the third quarter. Aperio Group LLC now owns 13,183 shares of the specialty pharmaceutical company’s stock worth $135,000 after buying an additional 1,690 shares during the period. Finally, Rational Advisors LLC purchased a new stake in shares of SciClone Pharmaceuticals during the second quarter worth about $140,000. 75.68% of the stock is owned by hedge funds and other institutional investors.
About SciClone Pharmaceuticals
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.